Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has not spread or grown after initial treatment with certain types of chemotherapy (maintenance treatment) / after receiving at least 1 chemotherapy regimen (2nd/3rd-line treatment).
Reportedly, OSI, Genentech and Pfizer filed a case against Teva on 19 March 2009 with regard to US Patent Nos. 6,900,221, RE 41,065 and 7,087,613 for Tarceva tablets.
As a result, the case against Teva will be terminated by a Consent Order of Dismissal.